While TAZ knockdown can attenuate cell growth by inhibiting the PI3K/AkT/mTOR signaling pathway, it additionally leads to a compensatory YAP upregulation and expression of CD90, a HCC-specific tumor stem cell marker. The gene discussed is AKT1; the disease is hepatocellular carcinoma.